Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.
Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.
Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.
With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.
Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.
Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.
Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.
As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.
Evotec SE will announce its financial results for the first nine months of 2022 on November 9, 2022. A conference call will be held on the same day at 2:00 PM CET to discuss these results and provide a performance update. Participants can join via phone or through an audio webcast. Evotec operates globally with over 4,500 employees and focuses on discovering and developing therapeutics across various therapeutic areas, including neurology and oncology.
Evotec SE announced the completion of its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd. This strategic move enhances Evotec's drug substance manufacturing capacity, particularly focusing on rare diseases and precision therapeutics. The facility, located in Halle/Westphalia, Germany, is now operational and employs around 60 experts in chemical manufacturing. Evotec plans significant investments to establish this site as a leading center for rare disease drug substance manufacturing in Europe.
Evotec SE presented a transformative update on biologics manufacturing at its Capital Markets Day, focusing on global access to biotherapeutics. The company’s subsidiary, Just - Evotec Biologics, showcased its integrated AI/ML-based technologies, emphasizing a paradigm shift in the industry. Significant highlights include a $49.9 million contract with the U.S. Department of Defense for monoclonal antibody prototypes and the groundbreaking of a new manufacturing facility in Toulouse, France. CEO Dr. Werner Lanthaler underscored the need for modernized manufacturing to enhance accessibility to essential therapies.
Evotec SE has launched a new translational partnership named Extend in collaboration with CDP Venture Capital and Angelini Ventures. This initiative aims to enhance drug discovery efforts by forming partnerships with esteemed academic institutions across Italy. The Extend initiative seeks to translate innovative academic research into actionable data, facilitating the creation of spin-off companies. Key institutions involved include Ospedale San Raffaele and several universities from Milan, Florence, and Padua. This venture is part of Evotec's broader strategy to foster innovation and accelerate commercialization of promising therapeutics.
Evotec has partnered with Hannover Medical School to create a molecular patient database for Sjogren's syndrome and systemic lupus erythematosus. The collaboration aims to enhance disease understanding through a unique longitudinal PanOmics database by analyzing biospecimens from hundreds of patients. Evotec will commercially exploit the data, while MHH will use it for academic research. This partnership could facilitate the development of personalized therapies for autoimmune diseases, addressing unmet medical needs.
Evotec SE launched its PanOmics data analysis platform, PanHunter, at Bio-IT World on October 18, 2022. This software-as-a-service (SaaS) product aims to empower scientists by providing comprehensive access to vast PanOmics data sets, accelerating R&D processes and improving drug discovery success rates. With a significant increase in publicly available PanOmics data, PanHunter is designed to stratify patient populations and predict drug efficacy and toxicity, marking a notable advancement in data-driven medicine.
Evotec and Toronto Innovation Acceleration Partners (TIAP) have expanded their LAB150 partnership to include Amgen as a strategic partner, committing a combined investment of US$ 14 million. This collaboration aims to enhance the development of Canada's life science companies by streamlining the transition from academic research to market-ready products. LAB150 has evaluated over 150 projects and currently supports 10 projects. Amgen will provide financial backing and mentorship to these initiatives, accelerating commercialization efforts and fostering innovation in the sector.
Evotec SE (NASDAQ: EVO) and Toronto Innovation Acceleration Partners (TIAP) announced the expansion of their LAB150 partnership to include Amgen, with a combined investment of US$14M. This partnership aims to enhance the efficiency of academic research in Canada, focusing on drug discovery and commercialization. Amgen will provide mentorship and evaluate LAB150 projects for venture investment. Since its inception in 2017, LAB150 has supported over 150 projects with US$7M in investments. The partnership is expected to accelerate the formation of life science companies in Canada, strengthening its biotech ecosystem.
Evotec SE announced a contract with the U.S. Department of Defense valued up to $49.9 million for the rapid development of monoclonal antibody drug prototypes targeting plague. Under this contract, Just - Evotec Biologics will advance mAb prototypes from initial discovery to Phase I clinical trials using its J.DESIGN platform, which integrates AI and machine learning. The goal is to produce effective medical countermeasures against plague, enhancing national security. The work will take place at Evotec's Redmond, Washington facility, part of the DOD's Advanced Development and Manufacturing network.
Evotec has begun construction of its J.POD ® biologics manufacturing facility in Toulouse, France, expected to be operational in H2 2024. This facility will utilize advanced J.POD ® technology to enhance clinical and commercial manufacturing capacity for biologics, addressing challenges in traditional manufacturing methods. The project is backed by funding from the French government and the Occitanie Region and is anticipated to create over 150 high-skill jobs in the area.
Evotec operates globally and focuses on the development of therapeutics across various medical areas.
FAQ
What is the current stock price of Evotec SE American Depositary Shares (EVO)?
What is the market cap of Evotec SE American Depositary Shares (EVO)?
What is Evotec SE?
What are Evotec's main business segments?
Who are Evotec's partners?
What recent collaborations has Evotec entered into?
How many employees does Evotec have?
What are Evotec's key therapeutic areas?
What financial performance did Evotec report in 2023?
What are the future goals of Evotec?
What is Just-Evotec Biologics?
What makes Evotec's platform unique?
